Stada is stepping up its presence in China’s consumer health market by partnering with local player CR Sanjiu.
The deal is initially focused on expanding the distribution and promotion of Stada’s cough and cold brands in China but...
Stada Grows China Presence Through CR Sanjiu Partnership
Listen to this article
Stada has struck a deal with CR Sanjiu for distribution and promotion of its cough and cold brands after identifying expansion in the Chinese market as a key strategic target.
Stay ahead of every shift in generics and biosimilars.
More from Deals
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
More from Business
• By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
• By
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.